March 26, 2020 11:00 UTC Karuna Therapeutics to Participate in Stifel’s 2 nd Annual CNS Day Virtual Event BOSTON--( BUSINESS WIRE )-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna The
Karuna Therapeutics to Participate in Stifel’s 2nd Annual CNS Day Virtual Event
BOSTON--(BUSINESS WIRE)-- Karuna Pharmaceuticals, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics will participate in a panel presentation at Stifel’s 2nd Annual CNS Day Virtual Event on Wednesday, April 1, 2020.
About Karuna
Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders – which remain among the most disabling and potentially fatal disorders worldwide. Galvanized by the understanding that today’s neuropsychiatric and pain management patients deserve better, Karuna’s mission is to harness the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways that will advance the standard of care. For more information, please visit karunatx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005100/en/
Contacts
Investor Contact:
Chris Brinzey
Westwicke, an ICR Company
+1 339 970-2843
chris.brinzey@westwicke.com
Media Contact:
Jenn Gordon
GlobalHealthPR
+1 202 587-2580
jgordon@globalhealthpr.com
Source: Karuna Therapeutics, Inc.